<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20250331230729&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20250331230729&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 01 Apr 2025 03:07:29 +0000</lastbuilddate>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Cardiac Biomarkers in Patients with Asymptomatic Severe Aortic Stenosis: Analysis from the EARLY TAVR Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163596/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331230729&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with asymptomatic severe high gradient AS, higher NT-proBNP and hs-cTnT levels were broadly associated with higher event rates as expected. However, the relative benefit of an early TAVR strategy was consistent regardless of baseline biomarker levels and, contrary to our hypothesis, tended to be more pronounced in those with the lowest biomarker levels. These findings suggest limited value for single measurements of these biomarkers to guide the timing of TAVR in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 31. doi: 10.1161/CIRCULATIONAHA.125.074425. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The EARLY TAVR trial demonstrated that early transcatheter aortic valve replacement (TAVR) intervention was superior to clinical surveillance (CS) with delayed TAVR in patients with asymptomatic, severe aortic stenosis (AS). Cardiac biomarkers are associated with maladaptive remodeling, symptom onset, and worse outcomes after TAVR. Whether elevated biomarkers identify asymptomatic patients more likely to benefit from early intervention is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A core laboratory measured N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high sensitivity cardiac troponin T (hs-cTnT). Associations between biomarker levels and risk of the trial primary endpoint (death, stroke, or unplanned cardiovascular hospitalization) and other secondary endpoints were examined with Kaplan-Meier curves and Cox proportional hazard models. Interaction tests were performed to assess whether the treatment effect of early TAVR, compared with CS, differed according to biomarker levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 901 patients randomized in EARLY TAVR, 798 (89%) had biospecimens measured (median NT-proBNP 287 [145, 601]; median hs-cTnT 14.6 [10.5, 21.0]). Higher levels of NT-proBNP and hs-cTnT were broadly associated with higher event rates for multiple endpoints. In general, there was no significant interaction between baseline biomarkers and treatment group with respect to any composite or individual endpoint examined, although trends broadly demonstrated a greater relative benefit of early TAVR at lower biomarker levels. There was a significant interaction between hs-cTnT and treatment group with respect to death or heart failure hospitalization (HFH) (interaction p=0.04) and HFH alone (interaction p=0.03) such that the relative benefit of early TAVR was greater for patients with normal, rather than elevated, levels of hs-cTnT at baseline. For some endpoints, higher baseline NT-proBNP was associated with numerically greater absolute risk reduction with early TAVR than lower NT-proBNP levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with asymptomatic severe high gradient AS, higher NT-proBNP and hs-cTnT levels were broadly associated with higher event rates as expected. However, the relative benefit of an early TAVR strategy was consistent regardless of baseline biomarker levels and, contrary to our hypothesis, tended to be more pronounced in those with the lowest biomarker levels. These findings suggest limited value for single measurements of these biomarkers to guide the timing of TAVR in asymptomatic patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163596/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331230729&v=2.18.0.post9+e462414">40163596</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.125.074425>10.1161/CIRCULATIONAHA.125.074425</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163596</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Brian R Lindman</dc:creator>
<dc:creator>Philippe Pibarot</dc:creator>
<dc:creator>Allan Schwartz</dc:creator>
<dc:creator>J Bradley Oldemeyer</dc:creator>
<dc:creator>Yan Ru Su</dc:creator>
<dc:creator>Kashish Goel</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>William F Fearon</dc:creator>
<dc:creator>Vasilis Babaliaros</dc:creator>
<dc:creator>David Daniels</dc:creator>
<dc:creator>Adnan Chhatriwalla</dc:creator>
<dc:creator>Hussam S Suradi</dc:creator>
<dc:creator>Pinak Shah</dc:creator>
<dc:creator>Molly Szerlip</dc:creator>
<dc:creator>Michael J Mack</dc:creator>
<dc:creator>Thom Dahle</dc:creator>
<dc:creator>William W O'Neill</dc:creator>
<dc:creator>Charles J Davidson</dc:creator>
<dc:creator>Raj Makkar</dc:creator>
<dc:creator>Tej Sheth</dc:creator>
<dc:creator>Jeremiah Depta</dc:creator>
<dc:creator>James T DeVries</dc:creator>
<dc:creator>Jeffrey Southard</dc:creator>
<dc:creator>Andrei Pop</dc:creator>
<dc:creator>Paul Sorajja</dc:creator>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>Yanglu Zhao</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Philippe Généreux</dc:creator>
<dc:creator>EARLY TAVR Trial Executive Committee and Study Investigators</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiac Biomarkers in Patients with Asymptomatic Severe Aortic Stenosis: Analysis from the EARLY TAVR Trial</dc:title>
<dc:identifier>pmid:40163596</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.125.074425</dc:identifier>
</item>
<item>
<title>Correction to: 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163565/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331230729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):e865. doi: 10.1161/CIR.0000000000001328. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331230729&v=2.18.0.post9+e462414">40163565</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001328>10.1161/CIR.0000000000001328</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163565</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Sunil V Rao</dc:creator>
<dc:creator>Michelle L O'Donoghue</dc:creator>
<dc:creator>Marc Ruel</dc:creator>
<dc:creator>Tanveer Rab</dc:creator>
<dc:creator>Jaqueline E Tamis-Holland</dc:creator>
<dc:creator>John H Alexander</dc:creator>
<dc:creator>Usman Baber</dc:creator>
<dc:creator>Heather Baker</dc:creator>
<dc:creator>Mauricio G Cohen</dc:creator>
<dc:creator>Mercedes Cruz-Ruiz</dc:creator>
<dc:creator>Leslie L Davis</dc:creator>
<dc:creator>James A de Lemos</dc:creator>
<dc:creator>Tracy A DeWald</dc:creator>
<dc:creator>Islam Y Elgendy</dc:creator>
<dc:creator>Dmitriy N Feldman</dc:creator>
<dc:creator>Abhinav Goyal</dc:creator>
<dc:creator>Ijeoma Isiadinso</dc:creator>
<dc:creator>Venu Menon</dc:creator>
<dc:creator>David A Morrow</dc:creator>
<dc:creator>Debabrata Mukherjee</dc:creator>
<dc:creator>Elke Platz</dc:creator>
<dc:creator>Susan B Promes</dc:creator>
<dc:creator>Sigrid Sandner</dc:creator>
<dc:creator>Yader Sandoval</dc:creator>
<dc:creator>Rachel Schunder</dc:creator>
<dc:creator>Binita Shah</dc:creator>
<dc:creator>Jason P Stopyra</dc:creator>
<dc:creator>Amy W Talbot</dc:creator>
<dc:creator>Pam R Taub</dc:creator>
<dc:creator>Marlene S Williams</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:40163565</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001328</dc:identifier>
</item>
<item>
<title>The Future Is Now: Paradigm Shifts in Heart Transplantation in the United States</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163564/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331230729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):910-912. doi: 10.1161/CIRCULATIONAHA.125.073544. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163564/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331230729&v=2.18.0.post9+e462414">40163564</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.125.073544>10.1161/CIRCULATIONAHA.125.073544</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163564</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Terrence M Yau</dc:creator>
<dc:creator>Subodh Verma</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The Future Is Now: Paradigm Shifts in Heart Transplantation in the United States</dc:title>
<dc:identifier>pmid:40163564</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.125.073544</dc:identifier>
</item>
<item>
<title>Correction to: Prenatal Lipopolysaccharides Exposure Induces Transgenerational Inheritance of Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163563/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331230729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):e866. doi: 10.1161/CIR.0000000000001325. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163563/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331230729&v=2.18.0.post9+e462414">40163563</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001325>10.1161/CIR.0000000000001325</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163563</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Nian Cao</dc:creator>
<dc:creator>Cong Lan</dc:creator>
<dc:creator>Caiyu Chen</dc:creator>
<dc:creator>Zaicheng Xu</dc:creator>
<dc:creator>Hao Luo</dc:creator>
<dc:creator>Shuo Zheng</dc:creator>
<dc:creator>Xue Gong</dc:creator>
<dc:creator>Hongmei Ren</dc:creator>
<dc:creator>Zhuxin Li</dc:creator>
<dc:creator>Shuang Qu</dc:creator>
<dc:creator>Cheng Yu</dc:creator>
<dc:creator>Jining Yang</dc:creator>
<dc:creator>Pedro A Jose</dc:creator>
<dc:creator>Yundai Chen</dc:creator>
<dc:creator>Gengze Wu</dc:creator>
<dc:creator>Cuimei Hu</dc:creator>
<dc:creator>Junyi Yu</dc:creator>
<dc:creator>Chunyu Zeng</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Prenatal Lipopolysaccharides Exposure Induces Transgenerational Inheritance of Hypertension</dc:title>
<dc:identifier>pmid:40163563</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001325</dc:identifier>
</item>
<item>
<title>Correction to: Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163562/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331230729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):e864. doi: 10.1161/CIR.0000000000001326. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163562/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331230729&v=2.18.0.post9+e462414">40163562</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001326>10.1161/CIR.0000000000001326</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163562</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Jonathan H Kim</dc:creator>
<dc:creator>Aaron L Baggish</dc:creator>
<dc:creator>Benjamin D Levine</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>Elizabeth H Dineen</dc:creator>
<dc:creator>J Sawalla Guseh</dc:creator>
<dc:creator>Andre La Gerche</dc:creator>
<dc:creator>Rachel Lampert</dc:creator>
<dc:creator>Matthew W Martinez</dc:creator>
<dc:creator>Michael Papadakis</dc:creator>
<dc:creator>Dermot M Phelan</dc:creator>
<dc:creator>Keri M Shafer</dc:creator>
<dc:creator>American Heart Association Leadership Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Peripheral Vascular Disease; and American College of Cardiology</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology</dc:title>
<dc:identifier>pmid:40163562</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001326</dc:identifier>
</item>
<item>
<title>Correction to: Update on Diagnosis and Management of Kawasaki Disease: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163561/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331230729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):e863. doi: 10.1161/CIR.0000000000001324. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163561/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331230729&v=2.18.0.post9+e462414">40163561</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001324>10.1161/CIR.0000000000001324</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163561</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Pei-Ni Jone</dc:creator>
<dc:creator>Adriana Tremoulet</dc:creator>
<dc:creator>Nadine Choueiter</dc:creator>
<dc:creator>Samuel R Dominguez</dc:creator>
<dc:creator>Ashraf S Harahsheh</dc:creator>
<dc:creator>Yoshihide Mitani</dc:creator>
<dc:creator>Meghan Zimmerman</dc:creator>
<dc:creator>Ming-Tai Lin</dc:creator>
<dc:creator>Kevin G Friedman</dc:creator>
<dc:creator>American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Radiology and Intervention; and Council on Clinical Cardiology</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Update on Diagnosis and Management of Kawasaki Disease: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:40163561</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001324</dc:identifier>
</item>
<item>
<title>Response by Yu and Cheng to Letter Regarding Article, "Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163560/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331230729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):e769-e770. doi: 10.1161/CIRCULATIONAHA.124.073362. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163560/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331230729&v=2.18.0.post9+e462414">40163560</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.073362>10.1161/CIRCULATIONAHA.124.073362</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163560</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Miao Yu</dc:creator>
<dc:creator>Xiang Cheng</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Yu and Cheng to Letter Regarding Article, "Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial"</dc:title>
<dc:identifier>pmid:40163560</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.073362</dc:identifier>
</item>
<item>
<title>Return to Play With Genetic Heart Disease: The Importance of Developing a Personalized Emergency Action Plan</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163559/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331230729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):893-895. doi: 10.1161/CIRCULATIONAHA.124.072830. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163559/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331230729&v=2.18.0.post9+e462414">40163559</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072830>10.1161/CIRCULATIONAHA.124.072830</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163559</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Belinda Gray</dc:creator>
<dc:creator>Rachel Lampert</dc:creator>
<dc:creator>Michael Papadakis</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Return to Play With Genetic Heart Disease: The Importance of Developing a Personalized Emergency Action Plan</dc:title>
<dc:identifier>pmid:40163559</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072830</dc:identifier>
</item>
<item>
<title>Letter by Kakizaki and Räber Regarding Article, "Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163558/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331230729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):e767-e768. doi: 10.1161/CIRCULATIONAHA.124.072950. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163558/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331230729&v=2.18.0.post9+e462414">40163558</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072950>10.1161/CIRCULATIONAHA.124.072950</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163558</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Ryota Kakizaki</dc:creator>
<dc:creator>Lorenz Räber</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Kakizaki and Räber Regarding Article, "Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial"</dc:title>
<dc:identifier>pmid:40163558</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072950</dc:identifier>
</item>
<item>
<title>Paternal Cardiac Lesion Induces Cardiac Adaptation in Offspring</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163557/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331230729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):968-971. doi: 10.1161/CIRCULATIONAHA.124.070323. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163557/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331230729&v=2.18.0.post9+e462414">40163557</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070323>10.1161/CIRCULATIONAHA.124.070323</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163557</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Benedetta Coppe</dc:creator>
<dc:creator>María Galardi-Castilla</dc:creator>
<dc:creator>Andrés Sanz-Morejón</dc:creator>
<dc:creator>Prateek Arora</dc:creator>
<dc:creator>Javier Lucas</dc:creator>
<dc:creator>Casie Iciek</dc:creator>
<dc:creator>Laura Lalaguna</dc:creator>
<dc:creator>Enrique Lara-Pezzi</dc:creator>
<dc:creator>Ignacio Flores</dc:creator>
<dc:creator>Nadia Mercader</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Paternal Cardiac Lesion Induces Cardiac Adaptation in Offspring</dc:title>
<dc:identifier>pmid:40163557</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070323</dc:identifier>
</item>
<item>
<title>From the Literature</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163556/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331230729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):966-967. doi: 10.1161/CIRCULATIONAHA.125.074395. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163556/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331230729&v=2.18.0.post9+e462414">40163556</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.125.074395>10.1161/CIRCULATIONAHA.125.074395</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163556</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Tracy Hampton</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>From the Literature</dc:title>
<dc:identifier>pmid:40163556</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.125.074395</dc:identifier>
</item>
<item>
<title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163551/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331230729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 3;150(23):1898-1903. doi: 10.1161/CIRCULATIONAHA.124.072974. Epub 2024 Dec 2.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163551/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331230729&v=2.18.0.post9+e462414">40163551</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072974>10.1161/CIRCULATIONAHA.124.072974</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163551</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</dc:title>
<dc:identifier>pmid:40163551</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072974</dc:identifier>
</item>
<item>
<title>Cardiovascular Health Among Rural and Urban US Adults-Healthcare, Lifestyle, and Social Factors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163358/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331230729&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: This national cross-sectional study found substantial rural-urban disparities in cardiometabolic risk factors and cardiovascular diseases, which were largest among younger adults and almost entirely explained by social risk factors. These findings suggest that efforts to improve socioeconomic conditions in rural communities may be critical to address the rural-urban gap in cardiovascular health.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 31. doi: 10.1001/jamacardio.2025.0538. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Improving cardiovascular health in rural areas is a national priority in the US. However, little is known about the current state of rural cardiovascular health and the underlying drivers of any rural-urban disparities.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To compare rates of cardiometabolic risk factors and cardiovascular diseases between rural and urban US adults and to evaluate the extent to which health care access, lifestyle factors, and social risk factors contribute to any rural-urban differences.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This nationally representative cross-sectional study analyzed data from US adults aged 20 years or older residing in rural vs urban areas using the 2022 National Health Interview Survey. Data were analyzed between August 2024 and February 2025.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: County-level rurality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcomes were age-standardized rates of cardiometabolic risk factors (hypertension, hyperlipidemia, obesity, and diabetes) and cardiovascular diseases (coronary heart disease [CHD] and stroke).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study population consisted of 27 172 adults, including 4256 adults (14.0%) residing in rural areas, 14 741 (54.8%) in small or medium metropolitan areas, and 8175 (31.2%) in urban areas. Mean (SD) participant age was 49.1 (17.8) years, and 4399 participants (50.8%) were female. Compared with their urban counterparts, rural adults were more likely to smoke, be insufficiently physically active, and have more social risk factors. Age-standardized rates of cardiometabolic risk factors were significantly higher in rural areas, including hypertension (37.1% vs 30.9%; rate ratio [RR], 1.20; 95% CI, 1.13-1.27), hyperlipidemia (29.3% vs 26.7%; RR, 1.10; 95% CI, 1.03-1.18), obesity (41.1% vs 30.0%; RR, 1.37; 95% CI, 1.27-1.47), and diabetes (11.2% vs 9.8%; RR, 1.15; 95% CI, 1.02-1.29). The same pattern was observed for CHD (6.7% vs 4.3%; RR, 1.58; 95% CI, 1.35-1.85), but no differences were observed for stroke. The magnitude of rural-urban disparities was largest among young adults (aged 20-39 years) for hypertension (RR, 1.44; 95% CI, 1.12-1.86), obesity (RR, 1.54; 95% CI, 1.34-1.77), and diabetes (RR, 2.59; 95% CI, 1.54-4.38). Rural-urban disparities in cardiovascular health were not meaningfully attenuated after adjustment for measures of health care access (insurance coverage, usual source of care, and recent health care utilization) and lifestyle factors (smoking and physical activity). However, accounting for social risk factors (poverty, education level, food insecurity, and home ownership) completely attenuated rural-urban disparities in hypertension (adjusted RR [aRR], 0.99; 95% CI, 0.93-1.06), diabetes (aRR, 1.02; 95% CI, 0.90-1.15), and CHD (aRR, 1.08; 95% CI, 0.91-1.29), but only partially attenuated disparities in obesity (aRR, 1.29; 95% CI, 1.20-1.39).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This national cross-sectional study found substantial rural-urban disparities in cardiometabolic risk factors and cardiovascular diseases, which were largest among younger adults and almost entirely explained by social risk factors. These findings suggest that efforts to improve socioeconomic conditions in rural communities may be critical to address the rural-urban gap in cardiovascular health.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163358/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331230729&v=2.18.0.post9+e462414">40163358</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0538>10.1001/jamacardio.2025.0538</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163358</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Michael Liu</dc:creator>
<dc:creator>Lucas X Marinacci</dc:creator>
<dc:creator>Karen E Joynt Maddox</dc:creator>
<dc:creator>Rishi K Wadhera</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Cardiovascular Health Among Rural and Urban US Adults-Healthcare, Lifestyle, and Social Factors</dc:title>
<dc:identifier>pmid:40163358</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0538</dc:identifier>
</item>
<item>
<title>Rural America-Expanding the Lens of Health Disparities: Endorsing the Need for Health Equity Research</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163356/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331230729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 31. doi: 10.1001/jamacardio.2025.0555. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163356/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331230729&v=2.18.0.post9+e462414">40163356</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0555>10.1001/jamacardio.2025.0555</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163356</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Rural America-Expanding the Lens of Health Disparities: Endorsing the Need for Health Equity Research</dc:title>
<dc:identifier>pmid:40163356</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0555</dc:identifier>
</item>
<item>
<title>Mining the Electronic Medical Record for Hypertension Treatment-Hope or Hype?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40162966/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331230729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 31. doi: 10.1001/jamacardio.2025.0842. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40162966/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331230729&v=2.18.0.post9+e462414">40162966</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0842>10.1001/jamacardio.2025.0842</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40162966</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Mining the Electronic Medical Record for Hypertension Treatment-Hope or Hype?</dc:title>
<dc:identifier>pmid:40162966</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0842</dc:identifier>
</item>
<item>
<title>Leveraging Preexisting Cardiovascular Data to Improve the Detection and Treatment of Hypertension: The NOTIFY-LVH Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40162953/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331230729&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In the NOTIFY-LVH randomized clinical trial, a centralized population health coordinator-led notification and clinical support pathway for individuals with LVH on prior echocardiograms increased the initial treatment of hypertension. This work highlights the potential benefit of leveraging preexisting but potentially underutilized cardiovascular data to improve health care delivery through mechanisms augmenting the traditional ambulatory care system.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 31. doi: 10.1001/jamacardio.2025.0871. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Hypertension is often underrecognized, leading to preventable morbidity and mortality. Tailored data systems combined with care augmented by trained nonphysicians have the potential to improve cardiovascular care.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine whether previously collected cardiovascular imaging data could be harnessed to improve the detection and treatment of hypertension through a system-level intervention.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The NOTIFY-LVH trial was a 2-arm, pragmatic randomized clinical trial conducted from March 2023 through June 2024 within the Mass General Brigham health care system, a multi-institutional network serving the greater Boston, Massachusetts, area. The study included individuals with a Mass General Brigham primary care affiliation who had left ventricular hypertrophy (LVH) on a prior echocardiogram, had no established cardiomyopathy diagnosis, and were not being treated with antihypertensive medications. Patients were followed for 12 months postintervention.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Population health coordinators contacted clinicians of patients randomized to the intervention, notifying them of LVH and offering assistance with follow-up care. A clinical support pathway-including 24-hour ambulatory blood pressure monitoring or cardiology referrals-was provided to aid LVH evaluation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was the initiation of an antihypertensive medication. Secondary outcomes included new hypertension and cardiomyopathy diagnoses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 648 patients were randomized-326 to the intervention and 322 to the control. Mean (SD) patient age was 59.4 (10.8) years and 248 patients (38.3%) were female. A total of 102 patients (15.7%) had a baseline diagnosis of hypertension and 109 patients (20.1%) had a mean outpatient blood pressure of 130/80 mm Hg or higher. Over 12 months, 53 patients (16.3%) in the intervention arm were prescribed an antihypertensive medication vs 16 patients (5.0%) in the control arm (adjusted odds ratio [OR], 3.76; 95% CI, 2.09-6.75; P &lt; .001). Individuals in the intervention group were also more likely to be diagnosed with hypertension (adjusted OR, 4.43; 95% CI, 2.36-8.33; P &lt; .001). Cardiomyopathy diagnoses did not significantly differ between groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In the NOTIFY-LVH randomized clinical trial, a centralized population health coordinator-led notification and clinical support pathway for individuals with LVH on prior echocardiograms increased the initial treatment of hypertension. This work highlights the potential benefit of leveraging preexisting but potentially underutilized cardiovascular data to improve health care delivery through mechanisms augmenting the traditional ambulatory care system.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05713916.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40162953/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331230729&v=2.18.0.post9+e462414">40162953</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0871>10.1001/jamacardio.2025.0871</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40162953</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Adam N Berman</dc:creator>
<dc:creator>Michael K Hidrue</dc:creator>
<dc:creator>Curtis Ginder</dc:creator>
<dc:creator>Linnea Shirkey</dc:creator>
<dc:creator>Japneet Kwatra</dc:creator>
<dc:creator>Anna C O'Kelly</dc:creator>
<dc:creator>Sean P Murphy</dc:creator>
<dc:creator>Jennifer M Searl Como</dc:creator>
<dc:creator>Danielle Daly</dc:creator>
<dc:creator>Yee-Ping Sun</dc:creator>
<dc:creator>William T Curry</dc:creator>
<dc:creator>Marcela G Del Carmen</dc:creator>
<dc:creator>Ron Blankstein</dc:creator>
<dc:creator>John A Dodson</dc:creator>
<dc:creator>David A Morrow</dc:creator>
<dc:creator>Benjamin M Scirica</dc:creator>
<dc:creator>Niteesh K Choudhry</dc:creator>
<dc:creator>James L Januzzi</dc:creator>
<dc:creator>Jason H Wasfy</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Leveraging Preexisting Cardiovascular Data to Improve the Detection and Treatment of Hypertension: The NOTIFY-LVH Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:40162953</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0871</dc:identifier>
</item>
<item>
<title>Survival Outcomes After Sudden Cardiac Arrest in Young Competitive Athletes From the United States</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40162942/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331230729&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Although survival from SCA among young competitive athletes in the United States has improved in the last decade, important racial disparities in outcomes were observed warranting additional research and prevention strategies.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 21:S0735-1097(25)05337-9. doi: 10.1016/j.jacc.2025.03.006. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Sudden cardiac arrest (SCA) is the leading cause of death among young competitive athletes during sports and exercise. A detailed analysis of survival outcomes should inform prevention strategies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to determine survival outcomes and trends following SCA among young competitive athletes in the United States and to explore outcomes based on race and exertional status.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This observational study identified cases of SCA among young competitive athletes through longitudinal surveillance by the National Center for Catastrophic Sports Injury Research from July 1, 2014, to June 30, 2023. Young athletes ≥11 years of age competing in middle school, high school, club, college, or semiprofessional/professional sports, and former athletes (within 1 year of participation) with SCA during exercise, rest, or sleep were included. The primary outcome was survival from SCA. Multivariable log binomial regression estimated survival proportion ratios by race and exertional status.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 641 athletes with SCA were identified during the 9-year study period (mean age 17 ± 3 years; 85% male). Overall survival was 49% (315 of 641). Survival from SCA occurring during exercise was 57% (275 of 481). The majority of cases were in high school athletes (61%), followed by college (15%) and middle school (12%) athletes. Overall survival (range 30%-66% per academic year; P = 0.007) and survival from exertional SCA (range 38%-72% per academic year; P = 0.03) both increased throughout the study period. Among exertional SCA events, survival was higher among athletes who experienced SCA during a game/competition vs practice/training (70% vs 53%; P = 0.001). Black race (RR: 0.63; 95% CI: 0.53-0.76), Other race (RR: 0.69; 95% CI: 0.50-0.94), and nonexertional SCA (RR: 0.43; 95% CI: 0.32-0.59) were associated with lower survival from SCA after adjusting for sex and level of competition.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Although survival from SCA among young competitive athletes in the United States has improved in the last decade, important racial disparities in outcomes were observed warranting additional research and prevention strategies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40162942/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331230729&v=2.18.0.post9+e462414">40162942</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.006>10.1016/j.jacc.2025.03.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40162942</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Bradley J Petek</dc:creator>
<dc:creator>Timothy W Churchill</dc:creator>
<dc:creator>Nathaniel Moulson</dc:creator>
<dc:creator>Randi Delong</dc:creator>
<dc:creator>Mary Catherine Minnig</dc:creator>
<dc:creator>Stephanie A Kliethermes</dc:creator>
<dc:creator>Aaron L Baggish</dc:creator>
<dc:creator>Joseph J Maleszewski</dc:creator>
<dc:creator>Kristen L Kucera</dc:creator>
<dc:creator>Kimberly G Harmon</dc:creator>
<dc:creator>Jonathan A Drezner</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Survival Outcomes After Sudden Cardiac Arrest in Young Competitive Athletes From the United States</dc:title>
<dc:identifier>pmid:40162942</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.006</dc:identifier>
</item>
<item>
<title>Early Intra-Aortic Balloon Support for Heart Failure-Related Cardiogenic Shock: A Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40162941/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331230729&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Routine early IABP plus standard care, compared with standard care, did not significantly improve survival or successful bridging to HRT in patients with HF-CS. (Study on Early Intra-aortic Balloon Pump Placement in Acute Decompensated Heart Failure Complicated by Cardiogenic Shock [Altshock-2]; NCT04369573).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 21:S0735-1097(25)05334-3. doi: 10.1016/j.jacc.2025.03.003. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The impact of intra-aortic balloon pump (IABP) on survival and successful bridging to heart replacement therapies (HRT) in patients with heart failure-cardiogenic shock (HF-CS) remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to evaluate the effect of early IABP use vs standard care on 60-day survival or successful bridging to HRT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In the multicenter, prospective Altshock-2 (Study on Early Intra-aortic Balloon Pump Placement in Acute Decompensated Heart Failure Complicated by Cardiogenic Shock), patients with Society for Cardiovascular Angiography and Interventions stage B, C, or D HF-CS and suitable for HRT were randomized to receive early IABP plus standard care (IABP group) or standard care (control group). The primary endpoint was survival or successful bridge to HRT at 60 days. Secondary endpoints included overall survival, maximum inotropic score, and maximum sequential organ failure assessment score.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In total, 53 patients were randomized to IABP and 48 to standard care. Patients were Society for Cardiovascular Angiography and Interventions stage B (28%, n = 28), C (57%, n = 56), and D (15%, n = 16). At the prespecified interim analysis, the trial was stopped because of futility. The primary endpoint was reached in 43 patients (81%) in the IABP group and 36 patients (75%) in the control group (HR: 0.72; 95% CI: 0.31-1.68; P = 0.45). A total of 37 patients (37%) underwent HRT within the 60-day follow-up. Four patients were escalated in the study group (7.5%) vs 2 in the control group (4.2%). Additionally, 6 patients (13%) initially assigned to standard care crossed over to IABP. Complications were comparable between groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Routine early IABP plus standard care, compared with standard care, did not significantly improve survival or successful bridging to HRT in patients with HF-CS. (Study on Early Intra-aortic Balloon Pump Placement in Acute Decompensated Heart Failure Complicated by Cardiogenic Shock [Altshock-2]; NCT04369573).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40162941/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331230729&v=2.18.0.post9+e462414">40162941</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.003>10.1016/j.jacc.2025.03.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40162941</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Nuccia Morici</dc:creator>
<dc:creator>Alice Sacco</dc:creator>
<dc:creator>Simone Frea</dc:creator>
<dc:creator>Matteo Rota</dc:creator>
<dc:creator>Luca Villanova</dc:creator>
<dc:creator>Carol Gravinese</dc:creator>
<dc:creator>Carlotta Sorini Dini</dc:creator>
<dc:creator>Nicoletta D'Ettore</dc:creator>
<dc:creator>Giulia Maj</dc:creator>
<dc:creator>Giulia D'Elio</dc:creator>
<dc:creator>Luciano Potena</dc:creator>
<dc:creator>Serafina Valente</dc:creator>
<dc:creator>Mario Sabatino</dc:creator>
<dc:creator>Giovanna Viola</dc:creator>
<dc:creator>Laura Garatti</dc:creator>
<dc:creator>Giovanni Amedeo Tavecchia</dc:creator>
<dc:creator>Letizia Bertoldi</dc:creator>
<dc:creator>Fabrizio Oliva</dc:creator>
<dc:creator>Navin K Kapur</dc:creator>
<dc:creator>Guido Tavazzi</dc:creator>
<dc:creator>Gaetano Maria De Ferrari</dc:creator>
<dc:creator>Federico Pappalardo</dc:creator>
<dc:creator>Altshock-2 Investigators</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Early Intra-Aortic Balloon Support for Heart Failure-Related Cardiogenic Shock: A Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:40162941</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.003</dc:identifier>
</item>
<item>
<title>Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40162940/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331230729&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The triad of obesity, HFpEF, and CKD identifies patients with considerable functional impairment and an unfavorable prognosis, who nevertheless respond favorably to tirzepatide. Long-term tirzepatide improves renal function (both by cystatin C and creatinine), but the measurement of eGFR in patients with obesity receiving incretin-based drugs is likely to be skewed by the effects of fat and muscle mass (and by changes in body composition) on the synthesis of both cystatin C and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 24:S0735-1097(25)05340-9. doi: 10.1016/j.jacc.2025.03.009. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Obesity leads to both heart failure with a preserved ejection fraction (HFpEF) and to chronic kidney disease (CKD); CKD may both influence the clinical course of obesity-related HFpEF; and incretin-based drugs may influence renal function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This analysis had dual objectives: 1) to evaluate the influence of CKD on the clinical responses to tirzepatide in patients with obesity-related HFpEF; and 2) to investigate the complexity of tirzepatide-related changes in renal function. For both objectives, we focused on discrepancies between creatinine-based and cystatin C-based estimates of the estimated glomerular filtration rate (eGFR).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The SUMMIT trial randomly assigned 731 patients with HFpEF and a body mass index ≥30 kg/m<sup>2</sup>, who were enriched for participants with CKD. Patients received either placebo or tirzepatide for a median of 104 weeks and were followed for cardiovascular death or worsening heart failure events and for changes in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) after 52 weeks. Because of the confounding produced by obesity and changes in muscle mass, eGFR was assessed at randomization and after 12, 24, and 52 weeks by both creatinine-based and cystatin C-based formulae.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Patients with CKD (based on creatinine or cystatin C) had greater severity of heart failure, as reflected by: 1) worse functional class, KCCQ-CSS scores, and 6-minute walk distance; 2) higher levels of NT-proBNP and cardiac troponin T; and 3) a 2-fold increase in the risk of worsening heart failure events. CKD did not influence the effect of tirzepatide to reduce the relative risk of major adverse heart failure events and to improve KCCQ-CSS, quality of life, and functional capacity, but the absolute risk reduction in the primary events was numerically greater in patients with CKD. Regarding renal function assessments, baseline eGFR-cystatin C was consistently ≈9 mL/min/1.73 m<sup>2</sup> lower than that eGFR-creatinine, with significant individual variance. Furthermore, tirzepatide increased eGFR at 52 weeks, assessed by both creatinine-based and cystatin C-based formulae, but with considerable discordance in individual patients. Tirzepatide produced a decline in eGFR at 12 weeks with eGFR-creatinine (but not eGFR-cystatin C), and it led to an improvement in eGFR at 52 weeks in all patients (when assessed by cystatin C), but only in patients with CKD (when assessed by eGFR-creatinine).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The triad of obesity, HFpEF, and CKD identifies patients with considerable functional impairment and an unfavorable prognosis, who nevertheless respond favorably to tirzepatide. Long-term tirzepatide improves renal function (both by cystatin C and creatinine), but the measurement of eGFR in patients with obesity receiving incretin-based drugs is likely to be skewed by the effects of fat and muscle mass (and by changes in body composition) on the synthesis of both cystatin C and creatinine. (A Study of Tirzepatide [LY3298176] in Participants With Heart Failure With Preserved Ejection Fraction [HFpEF] and Obesity: The SUMMIT Trial; NCT04847557).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40162940/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331230729&v=2.18.0.post9+e462414">40162940</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.009>10.1016/j.jacc.2025.03.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40162940</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>Michael R Zile</dc:creator>
<dc:creator>Christopher M Kramer</dc:creator>
<dc:creator>Masahiro Murakami</dc:creator>
<dc:creator>Yang Ou</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:creator>SUMMIT Trial Study Group</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial</dc:title>
<dc:identifier>pmid:40162940</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.009</dc:identifier>
</item>
<item>
<title>Bursting the Balloon: The End of Intra-Aortic Balloon Pumps for Cardiogenic Shock?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40162939/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331230729&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 21:S0735-1097(25)05833-4. doi: 10.1016/j.jacc.2025.03.479. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40162939/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331230729&v=2.18.0.post9+e462414">40162939</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.479>10.1016/j.jacc.2025.03.479</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40162939</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Clément Delmas</dc:creator>
<dc:creator>Miloud Cherbi</dc:creator>
<dc:creator>François Roubille</dc:creator>
<dc:creator>Christophe Vandenbriele</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Bursting the Balloon: The End of Intra-Aortic Balloon Pumps for Cardiogenic Shock?</dc:title>
<dc:identifier>pmid:40162939</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.479</dc:identifier>
</item>
<item>
<title>Centering Diné (Navajo) Voices: Barriers, Facilitators, and Perceptions of Cardiac Care among Patients with Heart Failure in Rural Navajo Nation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40162902/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250331230729&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: As the first qualitative study of American Indian patients with HF in the current era, these results highlight unique care challenges, which can inform community-designed strategies to improve access to care.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 31. doi: 10.1161/CIRCULATIONAHA.124.073166. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The American Indian population in the United States experiences marked cardiovascular health disparities. American Indian patients, particularly those receiving care rurally through the Indian Health Service (IHS), face unique challenges to accessing appropriate cardiovascular care. However, there are no studies in the current era characterizing these challenges from the patient perspective. Therefore, the aim of this study was to characterize the barriers, facilitators, and perceptions of cardiac care among Diné (Navajo) patients with heart failure (HF) receiving care through the IHS, as well as to determine patient-designed solutions to improve access to quality cardiovascular care.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We performed semi-structured interviews and surveys of Diné patients (n=30) living with heart failure receiving care at two IHS sites in rural Navajo Nation. The participants were 27% female, 30% Navajo speaking, with a median age of 59 (IQR 53,67) years. Interviews were guided by the Consolidation Framework for Implementation Research to describe patient experiences with receiving cardiac care. Interviews were audio-recorded and transcribed for thematic analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Several themes emerged reflecting barriers and facilitators to accessing cardiac care, as well as perspectives regarding HF care and advanced therapies. Primary barriers included lack of specialists locally, transportation-related and financial barriers to travel long distances to urban centers for care, complicated IHS referral processes, and mistrust of providers outside of the IHS. Facilitators included trust of local IHS care; community and family support; and exceptional patient and caregiver resiliency and activation. Most patients felt traditional medicine was important for their cardiovascular health and desired more of its integration into Western treatment. There was heterogeneity in cultural beliefs regarding heart transplantation, but the majority felt it was acceptable if needed. Proposed solutions for improving cardiovascular care included making more services available locally, increased telehealth options, and assistance for social determinants of health especially access to healthier food and transportation-related costs for referral care.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: As the first qualitative study of American Indian patients with HF in the current era, these results highlight unique care challenges, which can inform community-designed strategies to improve access to care.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40162902/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250331230729&v=2.18.0.post9+e462414">40162902</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.073166>10.1161/CIRCULATIONAHA.124.073166</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40162902</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Lauren Eberly</dc:creator>
<dc:creator>Ada Tennison</dc:creator>
<dc:creator>Larissa Morgan</dc:creator>
<dc:creator>Marita Smith</dc:creator>
<dc:creator>Leah Gray</dc:creator>
<dc:creator>Matthew Kearney</dc:creator>
<dc:creator>Benjamin Feliciano</dc:creator>
<dc:creator>Erica Lindsey</dc:creator>
<dc:creator>Jacob Manche</dc:creator>
<dc:creator>Pamela Detsoi-Smiley</dc:creator>
<dc:creator>Sonya Shin</dc:creator>
<dc:creator>Maricruz Merino</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Centering Diné (Navajo) Voices: Barriers, Facilitators, and Perceptions of Cardiac Care among Patients with Heart Failure in Rural Navajo Nation</dc:title>
<dc:identifier>pmid:40162902</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.073166</dc:identifier>
</item>





























</channel>
</rss>